Poehling Capital Management’s Biogen BIIB Stock Holding History

Poehling Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,144	Closed	-$210K	–	167
2026 Q1	$210K	Buy	+1,144	New	+$211K	0.04%	145

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Poehling Capital Management's BIIB Position: Q2 2026 in Review

Poehling Capital Management sold out of Biogen (BIIB) in Q2 2026, closing a stake of 1,144 shares — an estimated $210K sold.

Poehling Capital Management first reported a position in BIIB in Q1 2026 and held it in 1 quarter. The position peaked at $210K in Q1 2026. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Poehling Capital Management reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
Poehling Capital Management sold 1,144 Biogen shares in Q2 2026, an estimated $210K.
Poehling Capital Management first reported a position in Biogen in Q1 2026 and held it in 1 quarter.
Poehling Capital Management's Biogen position peaked at $210K in Q1 2026.
1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Poehling Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.